Entrada Therapeutics Announces Inducement Grants

Biotech firm grants restricted stock units to new hires under Nasdaq rules

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Entrada Therapeutics, a clinical-stage biopharmaceutical company, announced that it has granted an aggregate of 12,990 restricted stock units (RSUs) to two newly-hired non-executive employees under the company's 2025 Inducement Equity Plan. The inducement grants were approved by Entrada's Compensation Committee as a material inducement to the new employees' entry into employment with the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters

Entrada Therapeutics is a biotech firm focused on developing a new class of genetic medicines to treat various diseases. The inducement grants to new hires are a common practice in the industry to attract and retain top talent, and the announcement demonstrates the company's continued growth and investment in its pipeline.

The details

The RSUs will vest over time, with one-fourth vesting on the one-year anniversary of the vesting commencement date and 6.25% vesting quarterly thereafter. The RSUs are subject to the terms and conditions of Entrada's 2025 Inducement Equity Plan and the specific award agreements.

  • The inducement grants were effective as of March 1, 2026.
  • The RSUs will vest on March 1, June 1, September 1, and December 1 of each subsequent year.

The players

Entrada Therapeutics, Inc.

A clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of genetic medicines that engage intracellular targets.

Got photos? Submit your photos here. ›

The takeaway

Entrada Therapeutics' inducement grants to new hires demonstrate the company's continued growth and investment in its pipeline of genetic medicines, which could have a significant impact on the lives of patients with various diseases.